JP2018052983A5 - - Google Patents

Download PDF

Info

Publication number
JP2018052983A5
JP2018052983A5 JP2017251017A JP2017251017A JP2018052983A5 JP 2018052983 A5 JP2018052983 A5 JP 2018052983A5 JP 2017251017 A JP2017251017 A JP 2017251017A JP 2017251017 A JP2017251017 A JP 2017251017A JP 2018052983 A5 JP2018052983 A5 JP 2018052983A5
Authority
JP
Japan
Prior art keywords
blood
metabolic syndrome
subject
mmol
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017251017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018052983A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018052983A publication Critical patent/JP2018052983A/ja
Publication of JP2018052983A5 publication Critical patent/JP2018052983A5/ja
Pending legal-status Critical Current

Links

JP2017251017A 2009-08-12 2017-12-27 代謝性症候群を予防し又は治療するための方法 Pending JP2018052983A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12
US61/233,275 2009-08-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017039099A Division JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019073924A Division JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Publications (2)

Publication Number Publication Date
JP2018052983A JP2018052983A (ja) 2018-04-05
JP2018052983A5 true JP2018052983A5 (enExample) 2018-06-14

Family

ID=43586452

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012524836A Active JP5909182B2 (ja) 2009-08-12 2010-08-11 代謝性症候群を予防し又は治療するための方法
JP2015250186A Pending JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法
JP2017039099A Active JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法
JP2017251017A Pending JP2018052983A (ja) 2009-08-12 2017-12-27 代謝性症候群を予防し又は治療するための方法
JP2019073924A Pending JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2012524836A Active JP5909182B2 (ja) 2009-08-12 2010-08-11 代謝性症候群を予防し又は治療するための方法
JP2015250186A Pending JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法
JP2017039099A Active JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019073924A Pending JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Country Status (10)

Country Link
US (4) US20110039766A1 (enExample)
EP (4) EP3251686A1 (enExample)
JP (5) JP5909182B2 (enExample)
CN (3) CN105031605A (enExample)
CA (1) CA2770688C (enExample)
DK (1) DK2464371T3 (enExample)
ES (1) ES2576746T3 (enExample)
HK (1) HK1247820A1 (enExample)
HU (1) HUE029550T2 (enExample)
WO (1) WO2011019809A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025734A1 (en) 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP2764871A1 (en) 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
JP2015524439A (ja) 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
ES3058737T3 (en) * 2012-10-22 2026-03-12 Stealth Biotherapeutics Inc Treatment of left ventricular remodeling
EP3459598A1 (en) * 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
CN117752766A (zh) * 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
ES2750258T3 (es) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
JP6480921B2 (ja) * 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
JP2016540762A (ja) * 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
WO2017066659A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Jag1 expression predicts therapeutic response in nash
WO2017180535A1 (en) * 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CN108210914A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
JP7171671B2 (ja) * 2020-10-22 2022-11-15 野村マイクロ・サイエンス株式会社 超純水製造システム及び超純水製造方法
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
WO2001025188A1 (en) * 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
CA2416475C (en) * 2000-07-18 2011-10-11 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN100506841C (zh) * 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
WO2005051408A1 (en) * 2003-11-28 2005-06-09 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2947330C (en) * 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
CA2713150C (en) * 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure

Similar Documents

Publication Publication Date Title
JP2013501802A5 (enExample)
JP2022031772A5 (enExample)
JP2013533858A5 (enExample)
JP2007500236A5 (enExample)
JP2017507139A5 (enExample)
JP2012517478A5 (enExample)
JP2004504406A5 (enExample)
CA2513567A1 (en) Cop 1 for treatment of inflammatory bowel diseases
JP2013541583A5 (enExample)
JP2013518124A5 (enExample)
JP2003519228A5 (enExample)
JP2002528502A5 (enExample)
JP2017534618A5 (enExample)
JP2017514911A5 (enExample)
JP2020500864A5 (enExample)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
MX2007015085A (es) Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.
JP2012525358A5 (enExample)
JP2023531675A5 (enExample)
JP2011527317A5 (enExample)
JP2023523247A (ja) ウイルス感染症の治療のためのレニン－アンジオテンシン系（ｒａｓ）モジュレーター、それを含む医薬組成物、およびそれを用いた治療方法
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
JP2013523844A5 (enExample)
JP2010529125A5 (enExample)
JP2022521266A5 (enExample)